Nuclear medicine in cancer diagnosis
暂无分享,去创建一个
[1] J S Fowler,et al. Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] O. Hoekstra,et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[4] S. Hauptmann,et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. , 1994, Radiology.
[5] M. Kaminski,et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.
[6] G. Marchal,et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[7] T K Lewellen,et al. Carbon-11-thymidine and FDG to measure therapy response. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] L E Williams,et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.
[9] G. Denardo,et al. Trials and tribulations: oncological antibody imaging comes to the fore. , 1997, Seminars in nuclear medicine.
[10] T. Jones,et al. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. , 1995, European journal of cancer.
[11] M. Sasaki,et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma , 1996, Annals of nuclear medicine.
[12] A. Hendler,et al. When to use bone scintigraphy. It can reveal things other studies cannot. , 1998, Postgraduate medicine.
[13] L. Strauss,et al. The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. , 1993, The Journal of otolaryngology.
[14] R. Hawkins,et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. , 1993, International journal of radiation oncology, biology, physics.
[15] D. Bumann,et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] G. V. von Schulthess,et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. , 1998, The Annals of thoracic surgery.
[17] M E Phelps,et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] B. Karlan,et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. , 1993, Gynecologic oncology.
[19] T K Lewellen,et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.
[20] E. Krenning,et al. Somatostatin-receptor imaging in the localization of endocrine tumors. , 1990, The New England journal of medicine.
[21] D. Mankoff,et al. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). , 1997, Nuclear medicine and biology.
[22] J. Srigley,et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity , 1984 .
[23] M. Berger,et al. 2-[C-11]thymidine imaging of malignant brain tumors. , 1999, Cancer research.
[24] J. Hanke,et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] H. Minn,et al. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] Otto Warburn,et al. THE METABOLISM OF TUMORS , 1931 .
[27] J. Sunderland,et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1992, Radiology.
[28] G van Kaick,et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] D Delbeke,et al. Prospective investigation of positron emission tomography in lung nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Mankoff,et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] W. Chapman,et al. Staging recurrent metastatic colorectal carcinoma with PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] K L Lindsley,et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.
[33] L. Goldman,et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. , 1979, The New England journal of medicine.
[34] P. Gutin,et al. Differentiation of Cerebral Radiation Necrosis from Tumor Recurrence by [18F]FDG and 82Rb Positron Emission Tomography , 1987, Journal of computer assisted tomography.
[35] M. Mintun,et al. Breast cancer: PET imaging of estrogen receptors. , 1988, Radiology.
[36] R. Davis,et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] Bernard Bendriem,et al. In vivo imaging of oligonucleotides with positron emission tomography , 1998, Nature Medicine.
[38] W L Ashburn,et al. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. , 1984, AJR. American journal of roentgenology.
[39] J S Fowler,et al. A FLUORINATED GLUCOSE ANALOG, 2‐FLUORO-2‐DEOXY-D‐GLUCOSE (F‐18): NONTOXIC TRACER FOR RAPID TUMOR DETECTION , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] R Iwata,et al. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] T W Griffin,et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.